Effects of duration and number of symptoms on vision-related anxiety in patients with Inherited Retinal Diseases

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorPOPOVA, Lilia T. T.
dc.contributor.authorABUZAITOUN, Rebhi O. O.
dc.contributor.authorABALEM, Maria Fernanda
dc.contributor.authorANDREWS, Chris A. A.
dc.contributor.authorMONDUL, Alison M. M.
dc.contributor.authorLACY, Gabrielle D. D.
dc.contributor.authorMUSCH, David C. C.
dc.contributor.authorJAYASUNDERA, K. Thiran
dc.date.accessioned2023-04-14T18:08:03Z
dc.date.available2023-04-14T18:08:03Z
dc.date.issued2023
dc.description.abstractBackground: Patients with Inherited Retinal Diseases (IRDs) are at increased risk for vision-related anxiety due to progressive and irreversible vision loss, yet little is known about risk factors for anxiety in these patients. Materials and Methods: This was a single-center, retrospective cross-sectional study at a large academic center. 128 adults with an IRD and without other significant eye conditions were recruited between December 2016 and March 2020. Participants were asked about the duration and number of symptoms they had in the following vision domains: reading, contrast vision, color vision, glare/light sensitivity, night vision, and peripheral vision. The outcomes of interest were the two domains of the Michigan Vision-Related Anxiety Questionnaire (MVAQ), rod- and cone-function related anxiety. We conducted an adjusted analysis to isolate the independent effect of duration and number of symptoms on vision-related anxiety. Results: Of 126 participants had complete data, 62 (49%) were female and 64 (51%) were male, with an average age of 49 years (range: 18-87). Patients with duration of symptoms for greater than 25 years had an adjusted anxiety theta that was one-half standard deviations lower than patients with symptoms for less time. Patients with higher number of symptoms had higher anxiety theta after adjusting for confounding variables (p < 0.0001). Conclusions: The number of symptoms but not the duration of symptoms, is an independent risk factor for vision-related anxiety. Patients with more symptoms are at higher risk for vision-related anxiety. Having symptoms for longer than 25 years may reduce this anxiety.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationOPHTHALMIC GENETICS, v.44, n.1, p.11-18, 2023
dc.identifier.doi10.1080/13816810.2022.2144901
dc.identifier.eissn1744-5094
dc.identifier.issn1381-6810
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/53193
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS INCeng
dc.relation.ispartofOphthalmic Genetics
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright TAYLOR & FRANCIS INCeng
dc.subjectInherited retinal diseaseseng
dc.subjectvision-related anxietyeng
dc.subjectanxietyeng
dc.subjectlow-visioneng
dc.subjectpatient-reported outcomeseng
dc.subject.othervisual impairmenteng
dc.subject.othermental-healtheng
dc.subject.otherquestionnaireeng
dc.subject.otherprogressioneng
dc.subject.wosGenetics & Heredityeng
dc.subject.wosOphthalmologyeng
dc.titleEffects of duration and number of symptoms on vision-related anxiety in patients with Inherited Retinal Diseaseseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalPOPOVA, Lilia T. T.:Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI USA
hcfmusp.author.externalMONDUL, Alison M. M.:Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI USA
hcfmusp.author.externalLACY, Gabrielle D. D.:Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA
hcfmusp.author.externalMUSCH, David C. C.:Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI USA
hcfmusp.author.externalJAYASUNDERA, K. Thiran:Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA; Univ Michigan, Retinal Dystrophy Clin, Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA
hcfmusp.citation.scopus1
hcfmusp.contributor.author-fmusphcMARIA FERNANDA ABALEM DE SA CARRICONDO
hcfmusp.description.beginpage11
hcfmusp.description.endpage18
hcfmusp.description.issue1
hcfmusp.description.volume44
hcfmusp.origemWOS
hcfmusp.origem.pubmed36440767
hcfmusp.origem.scopus2-s2.0-85142866035
hcfmusp.origem.wosWOS:000892230100001
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceCumberland PM, 2016, JAMA OPHTHALMOL, V134, P959, DOI 10.1001/jamaophthalmol.2016.1778eng
hcfmusp.relation.referenceDemmin DL, 2020, CLIN OPHTHALMOL, V14, P4229, DOI 10.2147/OPTH.S258783eng
hcfmusp.relation.referenceDiniz A, 2016, OPHTHALMOLOGY, V123, P754, DOI 10.1016/j.ophtha.2015.12.014eng
hcfmusp.relation.referenceFrank CR, 2019, JAMA OPHTHALMOL, V137, P793, DOI 10.1001/jamaophthalmol.2019.1085eng
hcfmusp.relation.referenceGeorgiou M, 2021, CLIN EXP OPHTHALMOL, V49, P270, DOI 10.1111/ceo.13917eng
hcfmusp.relation.referenceGill JS, 2019, BRIT J OPHTHALMOL, V103, P711, DOI 10.1136/bjophthalmol-2018-313278eng
hcfmusp.relation.referenceHamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40eng
hcfmusp.relation.referenceHamel CP, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-7eng
hcfmusp.relation.referenceHolladay JT, 1997, J REFRACT SURG, V13, P388eng
hcfmusp.relation.referenceHolloway EE, 2015, AUSTRALAS J AGEING, V34, P229, DOI 10.1111/ajag.12159eng
hcfmusp.relation.referenceKroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004eng
hcfmusp.relation.referenceLacy GD, 2021, AM J OPHTHALMOL, V225, P137, DOI 10.1016/j.ajo.2020.12.001eng
hcfmusp.relation.referenceLacy GD, 2021, AM J OPHTHALMOL, V222, P60, DOI 10.1016/j.ajo.2020.08.032eng
hcfmusp.relation.referenceLacy GD, 2020, OPHTHALMIC GENET, V41, P315, DOI 10.1080/13816810.2020.1776337eng
hcfmusp.relation.referenceLam BL, 2008, ARCH OPHTHALMOL-CHIC, V126, P975, DOI 10.1001/archopht.126.7.975eng
hcfmusp.relation.referenceLowe B, 2010, J AFFECT DISORDERS, V122, P86, DOI 10.1016/j.jad.2009.06.019eng
hcfmusp.relation.referenceSainohira M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195983eng
hcfmusp.relation.referenceSenra H, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-06252-1eng
hcfmusp.relation.referencevan der Aa HPA, 2016, OPHTHAL PHYSL OPT, V36, P584, DOI 10.1111/opo.12313eng
hcfmusp.relation.referenceZahid S, 2014, ADV EXP MED BIOL, V801, P131, DOI 10.1007/978-1-4614-3209-8_17eng
hcfmusp.relation.referenceZhang XZ, 2013, JAMA OPHTHALMOL, V131, P573, DOI 10.1001/jamaophthalmol.2013.2597eng
hcfmusp.relation.referenceZheng YJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46453eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication5eb87610-bddf-4239-b93f-7279c62f9126
relation.isAuthorOfPublication.latestForDiscovery5eb87610-bddf-4239-b93f-7279c62f9126
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_POPOVA_Effects_of_duration_and_number_of_symptoms_on_2023.PDF
Tamanho:
1.09 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC